| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- J. Lipid Res. (5)
- Proc. Natl. Acad. Sci. U.S.A. (2)
- Am. J. Physiol. Gastrointest. Liver Physiol. (2)
- Others (26)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Carlson SA and Jones BD | Inhibition of Salmonella typhimurium invasion by host cell expression of secreted bacterial invasion proteins. | 1998 | Infect. Immun. | pmid:9784535 |
| SariahmetoÄŸlu M et al. | Effects of WEB 2086 on the protective role of preconditioning against arrhythmias in rats. | 1998 | Pharmacol. Res. | pmid:9782066 |
| Akisü M et al. | The effect of L-carnitine on platelet activating factor concentration in the immature rat model of hypoxic-ischemic brain injury. | 1998 | Acta Med. Okayama | pmid:9781268 |
| Serebruany VL et al. | Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. | 1998 | Cardiology | pmid:9778550 |
| Shah BH et al. | The inhibitory effect of cinchonine on human platelet aggregation due to blockade of calcium influx. | 1998 | Biochem. Pharmacol. | pmid:9776305 |
| Suzuki T et al. | 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. II. Structure-activity relationships and active configuration of 2-(3-pyridyl)thiazolidine-4-carboxamides as platelet-activating factor receptor antagonists. | 1998 | Chem. Pharm. Bull. | pmid:9775441 |
| Teather LA et al. | Effects of posttraining intrahippocampal injections of platelet-activating factor and PAF antagonists on memory. | 1998 | Neurobiol Learn Mem | pmid:9774526 |
| Perez S et al. | Inhibition by the anti-mitotic drug doxorubicin of platelet-activating-factor-induced late eosinophil accumulation in rats. | 1998 | Eur. J. Pharmacol. | pmid:9774255 |
| Abu-Zidan FM | Hope or hype for lexipafant? | 1998 | Nature | pmid:9774090 |
| Le Blanc K et al. | Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. | 1998 | Thromb. Res. | pmid:9772010 |